- Home
- AKTX vs RAPT Comparison
AKTX vs RAPT Comparison
Compare AKTX & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- RAPT
- Stock Information
- Founded
- AKTX N/A
- RAPT 2015
- Country
- AKTX United States
- RAPT United States
- Employees
- AKTX N/A
- RAPT N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- RAPT Health Care
- Exchange
- AKTX Nasdaq
- RAPT Nasdaq
- Market Cap
- AKTX 29.5M
- RAPT 30.8M
- IPO Year
- AKTX N/A
- RAPT 2019
- Fundamental
- Price
- AKTX $0.99
- RAPT $0.89
- Analyst Decision
- AKTX
- RAPT Hold
- Analyst Count
- AKTX 0
- RAPT 10
- Target Price
- AKTX N/A
- RAPT $5.00
- AVG Volume (30 Days)
- AKTX 91.8K
- RAPT 394.7K
- Earning Date
- AKTX 02-15-2025
- RAPT 11-12-2024
- Dividend Yield
- AKTX N/A
- RAPT N/A
- EPS Growth
- AKTX N/A
- RAPT N/A
- EPS
- AKTX N/A
- RAPT N/A
- Revenue
- AKTX N/A
- RAPT N/A
- Revenue This Year
- AKTX N/A
- RAPT N/A
- Revenue Next Year
- AKTX N/A
- RAPT N/A
- P/E Ratio
- AKTX N/A
- RAPT N/A
- Revenue Growth
- AKTX N/A
- RAPT N/A
- 52 Week Low
- AKTX $0.90
- RAPT $0.84
- 52 Week High
- AKTX $4.40
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- AKTX 31.38
- RAPT 36.23
- Support Level
- AKTX $0.95
- RAPT $0.84
- Resistance Level
- AKTX $1.13
- RAPT $1.18
- Average True Range (ATR)
- AKTX 0.15
- RAPT 0.10
- MACD
- AKTX 0.02
- RAPT 0.01
- Stochastic Oscillator
- AKTX 15.15
- RAPT 17.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.